Literature DB >> 9537229

Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells.

R V Blackburn1, S S Galoforo, P M Corry, Y J Lee.   

Abstract

Tumor cells that express a fusion gene comprised of Escherichia coli cytosine deaminase (CD) and herpes simplex virus type 1 thymidine kinase (TK) sequences exhibit activation of and subsequent killing by the normally innocuous prodrugs 5-fluorocytosine and ganciclovir (Rogulski et al., Hum. Gene Ther., 8: 73-85, 1997). To target localized expression of this therapeutic gene, we have constructed a recombinant adenovirus containing the CD-TK fusion gene under the control of a human inducible heat shock protein 70 promotional sequence. Strong expression of the fusion gene product was induced by heating at 41 degrees C for 1 h. Expression levels obtained were dependent on the multiplicity of infection used and the incubation time after heat shock. Heat-induced expression of the CD-TK protein significantly reduced the survival of PC-3 cells in the presence of both 5-fluorocytosine and ganciclovir. These studies represent a novel form of gene therapy for the transduction and regulation of a double suicide gene in tumor cells and may provide a unique application for hyperthermia in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9537229

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Prostate cancer: a comprehensive review.

Authors:  S N Pentyala; J Lee; K Hsieh; W C Waltzer; A Trocchia; L Musacchia; M J Rebecchi; S A Khan
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

Review 2.  Gene therapy for prostate cancer.

Authors:  J R Gingrich; R D Chauhan; M S Steiner
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

3.  Kadota Fund International Forum 2004. Application of thermal stress for the improvement of health, 15-18 June 2004, Awaji Yumebutai International Conference Center, Awaji Island, Hyogo, Japan. Final report.

Authors:  Tsutomu Sugahara; J van der Zee; Harm H Kampinga; Zeliko Vujaskovic; Motoharu Kondo; Takeo Ohnishi; Gloria Li; Heon J Park; Dennis B Leeper; Valentina Ostapenko; Elizabeth A Repasky; Masami Watanabe; Chang W Song
Journal:  Int J Hyperthermia       Date:  2008-03       Impact factor: 3.914

Review 4.  Chapter seven--Cancer treatment with gene therapy and radiation therapy.

Authors:  Sergey A Kaliberov; Donald J Buchsbaum
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

5.  High intensity focused ultrasound-induced gene activation in sublethally injured tumor cells in vitro.

Authors:  Yunbo Liu; Takashi Kon; Chuanyuan Li; Pei Zhong
Journal:  J Acoust Soc Am       Date:  2005-11       Impact factor: 1.840

6.  Inducible promoters for gene therapy of head and neck cancer: an in vitro study.

Authors:  Marianne Schmidt; Tonja Heimberger; Petra Gruensfelder; Gabriele Schler; Florian Hoppe
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-08-12       Impact factor: 2.503

7.  PET imaging of heat-inducible suicide gene expression in mice bearing head and neck squamous cell carcinoma xenografts.

Authors:  J J Parry; V Sharma; R Andrews; E G Moros; D Piwnica-Worms; B E Rogers
Journal:  Cancer Gene Ther       Date:  2008-08-29       Impact factor: 5.987

Review 8.  Gene therapy for prostate cancer.

Authors:  J R Gingrich; R D Chauhan; M S Steiner
Journal:  Curr Urol Rep       Date:  2001-06       Impact factor: 2.862

9.  Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery.

Authors:  Y Wang; Z Yang; S Liu; T Kon; A Krol; C-Y Li; F Yuan
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

10.  Imaging of conditional gene silencing in vivo using a bioluminescence-based method with thermo-inducible microRNAs.

Authors:  Karine Pinel; Coralie Genevois; Christelle Debeissat; Franck Couillaud
Journal:  Sci Rep       Date:  2018-03-16       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.